General
Preferred name
mevastatin
Synonyms
Compactin ()
ML 236B ()
ML-236B ()
ML236B ()
ML-236B,Compactin ()
ML-236B LACTONE ()
Mevastatina ()
NSC-281245 ()
L-637312 ()
NSC281245 ()
CS-500 ()
CS500 ()
Mevastatine ()
NSC-759322 ()
ML236B LACTONE ()
L637312 ()
P&D ID
PD002671
CAS
58948-09-7
73573-88-3
Tags
available
drug candidate
Drug Status
experimental
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
The primary cause of cardiovascular disease is atherosclerotic plaque formation. Mevastatin lowers hepatic production of cholesterol to reduce the risk of cardiovascular disease. Mevastatin competitively inhibits HMG-CoA reductase. This inhibition prevents the rate limiting step in cholesterol synthesis. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation.
PRICE
29
DESCRIPTION
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment[1][2][3].
DESCRIPTION
Mevastatin, originally isolated from Penicillium citrinum, was the first HMG-CoA reductase inhibitor (statin) to be identified .
Note, the structure presented here is a representative one, as there is some ambiguity in the stereoisomeric specification, see and for the primary references. (GtoPdb)
Note, the structure presented here is a representative one, as there is some ambiguity in the stereoisomeric specification, see and for the primary references. (GtoPdb)
DESCRIPTION
Antibiotic; inhibits post-translational prenylation of proteins such as Ras and geranylgeranylation of Rho
(LOPAC library)
DESCRIPTION
HMG-CoA reductase inhibitor
(Tocriscreen Plus)
DESCRIPTION
HMG-CoA reductase inhibitor
(Tocriscreen Total)
DESCRIPTION
Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Potent HMG-CoA reductase inhibitor
(Tocris Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
3
Compound Sets
16
AdooQ Bioactive Compound Library
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LINCS compound set
LOPAC library
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
38
Molecular Weight
390.24
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
3
Aromatic Ring Count
0
cLogP
3.95
TPSA
72.83
Fraction CSP3
0.74
Chiral centers
7.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Selectivity
Ras, Rho
Pathway
Apoptosis
Autophagy
Metabolism
Microbiology/virology
Anti-infection
Metabolic Enzyme/Protease
Primary Target
HMG-CoA Reductase
MOA
Inhibitor
HMGCR inhibitor
Target
HMGCR
antibiotic
Bacterial
HMG-CoA Reductase (HMGCR)
CES1
Source data
